Abstract
Serum concentrations of fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) are elevated in patients with CKD, and higher concentrations are well established as risk factors for cardiovascular disease and death ([1][1]). In the Systolic Blood Pressure Intervention Trial (SPRINT),
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have